| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| P-Selectin | Human P-Selectin / CD62P Protein, Fc Tag | Human | HEK293 | ![]() | SDS-PAGE | $270.00 100ug | ||
| P-Selectin | Human P-Selectin / CD62P Protein, His Tag | Human | HEK293 | ![]() | SDS-PAGE | $285.00 100ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Inclacumab | DSM-ACC-2641; RO 4905417; LC1004-002; DSM ACC2641; RG-1512; LC-1004-002; R-1512; PF-07940370; RO-4905417 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd, Genmab A/S | Anemia, Sickle Cell; Graft Occlusion, Vascular; Myocardial Infarction; Pain; Peripheral Arterial Disease | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Crizanlizumab | Sel-G-1; SEG-101; SEG101; Sel-G1 | Approved | Selexys Pharmaceuticals Corp | Adakveo, Ryverna | United States | Anemia, Sickle Cell | Novartis Pharmaceuticals Corp | 2019-11-15 | Anemia, Sickle Cell; Coronavirus Disease 2019 (COVID-19); Leukoencephalopathies; Priapism; Primary Myelofibrosis | Details |
